Leukemia drug Tasigna (nilotinib) may be linked to heart and circulation problems, some lawsuits allege.
Studies have allegedly linked the drug to serious cardiovascular side effects like Long QT syndrome, a condition involving irregular heartbeats, and atherosclerosis, a disease that causes plaque to build up in the arteries.
Injured patients and their families are now filing lawsuits against Tasigna manufacturer Novartis, alleging the company failed to warn of the drug’s cardiovascular risks. If you or a loved one suffered heart or circulation problems after taking Tasigna, contact us for a free, no-obligation case review to find out if you may be eligible for compensation.
Tasigna Cardiovascular Side Effects
More than 15,500 Tasigna-related adverse events and 2,786 deaths have been reported to the FDA to date.
More than 15,500 Tasigna-related adverse events and 2,786 deaths have allegedly been reported to the FDA to date. These include serious cardiovascular side effects, like Long QT syndrome, myocardial ischemia, and atherosclerosis.
Tasigna has one black box warning—the highest warning the FDA can issue—for Long QT syndrome, or QT interval prolongation, and sudden death. It’s a condition that affects heart rhythm, resulting in fast, irregular heartbeats. If left untreated, it can result in fainting, seizures, and sudden death.
Tasigna may also been linked to myocardial ischemia, a condition involving reduced blood flow to the heart, causing a decreased amount of oxygen sent to the heart. Myocardial ischemia is usually caused by a blockage of the coronary arteries.
Recent lawsuits have also been filed over the drug’s alleged connection to atherosclerosis, a disease that causes fatty deposits to build up and eventually clog arteries. This serious condition gradually reduces blood flow and oxygen to cells.
Atherosclerosis is currently the leading cause of death in the developed world. It may eventually cause the following complications:
- Coronary artery disease
- Peripheral arterial disease
- Blood clots
- Heart attacks
While Tasigna labels in Canada warn of a risk of developing atherosclerosis, in the U.S. injured patients allege Novartis has done little to warn of the condition.
Post-Market Studies Show Tasigna-Related Cardiovascular Risks
Recent studies have connected Tasigna with cardiovascular events.
In an FDA post-market review, 5.8% patients allegedly suffered ischemic heart disease-related events. Average Tasigna treatment length for patients was four years.
A 2011 Tasigna study discovered a similar risk for cardiovascular disease. Sixteen percent of the Tasigna patients examined developed peripheral arterial occlusive disease (PAOD)—a condition that involves a narrowing of the arteries—and 4% allegedly suffered a sudden death.
Tasigna Lawsuit Filed in California
The lawsuit alleges that Novartis failed to warn of the risk of developing atherosclerosis after taking Tasigna.
Patients who allegedly suffered heart and circulation problems after taking Tasigna are filing lawsuits against Novartis.
In March 2016, the family of a California man filed a Tasigna lawsuit—In RE: Lauris, et al. v. Novartis AG, et al—against Novartis, alleging the company failed to warn of the risk of developing atherosclerosis.
The man was prescribed Tasigna in 2012, and by September 2013, he allegedly showed signs of atherosclerosis. The condition caused him to develop peripheral artery disease, resulting in 90 to 100% artery blockages in his legs. Sadly, he died from atherosclerosis complications in March 2014.
Do You Qualify for a Tasigna Lawsuit?
If you or a loved one took Tasigna and suffered heart or circulation problems (including complications like blocked arteries, heart attacks, or strokes), you could be eligible to file a lawsuit against Novartis.
Filing a lawsuit may be able to help injured patients recover compensation for medical bills, lost wages (past and future), pain and suffering, and more.
We Want to Help You Hold Novartis Accountable
Our attorneys have led nationwide class action lawsuits against the largest pharmaceutical companies, like Johnson & Johnson and Bayer. With more than 400 attorneys across 50 offices, we have the resources to take on the biggest defendants.
Contact us today for a free, no-obligation case review. It never costs a thing unless we secure compensation for you.
Did you find what you need?